Albert T.
- Country
- France
- Department
- Hépato gastroentérologie et oncologie digestive
Research Overview
- Phase 3 Randomized Double-Blind Placebo-Controlled Trial of Efruxifermin in Non-Cirrhotic NASH/MASH with Fibrosis
- Evaluation of Semaglutide in Patients with Non-Cirrhotic Non-Alcoholic Steatohepatitis and Fibrosis Stages 2 or 3: A Randomized, Placebo-Controlled Trial
- Phase 1/2 Randomized, Placebo-Controlled Study of Nivolumab, Relatlimab, and Bevacizumab in Treatment-Naive Advanced/Metastatic Hepatocellular Carcinoma
Data & Insights
Has run more than one trial at 161 of 320 partner sites.
Specializations
Liver Metabolic Disorders
This investigator specializes in treating non-alcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH), conducting research on innovative therapeutic approaches for these conditions.
- Pre-cirrhotic NASH/MASH management
- Fibrosis regression studies
- Metabolic liver disease therapeutics
Hepatic Oncology
The investigator focuses on advanced treatments for hepatocellular carcinoma (HCC), particularly exploring combination immunotherapy approaches.
- First-line HCC treatment
- Advanced/metastatic liver cancer
- Immunotherapy combinations
Cholestatic Conditions
Research expertise includes the treatment of primary biliary cholangitis (PBC) and associated complications, with particular attention to symptom management.
- Cholestatic pruritus treatment
- PBC progression management
- Cirrhosis complications
Hepatic Complications
The investigator studies advanced liver disease complications, including hepatic encephalopathy and cirrhosis-related conditions.
- Encephalopathy prevention
- Compensated cirrhosis management
- Liver decompensation studies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.